EA200000687A1 - Производные арилтиазолидиндиона - Google Patents

Производные арилтиазолидиндиона

Info

Publication number
EA200000687A1
EA200000687A1 EA200000687A EA200000687A EA200000687A1 EA 200000687 A1 EA200000687 A1 EA 200000687A1 EA 200000687 A EA200000687 A EA 200000687A EA 200000687 A EA200000687 A EA 200000687A EA 200000687 A1 EA200000687 A1 EA 200000687A1
Authority
EA
Eurasian Patent Office
Prior art keywords
arylthiazolidine
derivatives
ppar
thiazolidinediones
hypertriglyceridemia
Prior art date
Application number
EA200000687A
Other languages
English (en)
Inventor
Соумиа П. Сахоо
Ричард Л. Толман
Вей Хан
Джеффри Бергман
Конрад Сантини
Виктория К. Ломбардо
Ранджит Десаи
Джулия К. Бауерс
Доминик Ф. Граталь
Original Assignee
Мерк Энд Ко., Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9816279.5A external-priority patent/GB9816279D0/en
Application filed by Мерк Энд Ко., Инк. filed Critical Мерк Энд Ко., Инк.
Publication of EA200000687A1 publication Critical patent/EA200000687A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/44—Two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

(57) Замещенные 5-арил-2,4-тиазолидиндионы представляют собой сильные агонисты PPAR и следовательно могут использоваться для лечения, контроля или профилактики диабета, гипергликемии, гиперлипидемии (включая гиперхолестеринемию и гипертриглицеридемию), атеросклероза, ожирения, сосудистого рестеноза и других PPAR α, β и/или γ опосредованных заболеваний, нарушений и болезненных состояний.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200000687A 1997-12-19 1998-12-18 Производные арилтиазолидиндиона EA200000687A1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US6827197P 1997-12-19 1997-12-19
GBGB9816279.5A GB9816279D0 (en) 1998-07-27 1998-07-27 Arylthiazolidinedione derivatives
US10523898P 1998-10-22 1998-10-22
PCT/US1998/027139 WO1999032465A1 (en) 1997-12-19 1998-12-18 Arylthiazolidinedione derivatives

Publications (1)

Publication Number Publication Date
EA200000687A1 true EA200000687A1 (ru) 2000-12-25

Family

ID=27269416

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200000687A EA200000687A1 (ru) 1997-12-19 1998-12-18 Производные арилтиазолидиндиона

Country Status (21)

Country Link
EP (1) EP1040102B1 (ru)
JP (1) JP3373198B2 (ru)
KR (1) KR20010033355A (ru)
CN (1) CN1282325A (ru)
AT (1) ATE352545T1 (ru)
AU (1) AU740733B2 (ru)
BG (1) BG104602A (ru)
BR (1) BR9813801A (ru)
CA (1) CA2315397C (ru)
DE (1) DE69836980T2 (ru)
EA (1) EA200000687A1 (ru)
ES (1) ES2281146T3 (ru)
HU (1) HUP0101366A2 (ru)
ID (1) ID24878A (ru)
IL (1) IL136138A0 (ru)
IS (1) IS5506A (ru)
NO (1) NO20003112L (ru)
PL (1) PL340958A1 (ru)
SK (1) SK9212000A3 (ru)
TR (1) TR200001753T2 (ru)
WO (1) WO1999032465A1 (ru)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9824614D0 (en) * 1998-11-11 1999-01-06 Glaxo Group Ltd Chemical compounds
EP1053989B1 (en) * 1999-05-20 2007-07-25 Ciba SC Holding AG Hydroxydiphenyl ether compounds
CA2376919C (en) * 1999-06-18 2008-11-04 Merck & Co., Inc. Arylthiazolidinedione and aryloxazolidinedione derivatives
AU5876900A (en) * 1999-06-18 2001-01-09 Merck & Co., Inc. Process for making arylthiazolidinedione derivatives
AU7073400A (en) * 1999-08-27 2001-03-26 Eli Lilly And Company Biaryl-oxa(thia)zole derivatives and their use as ppars modulators
PL356745A1 (en) * 1999-11-10 2004-06-28 Takeda Chemical Industries, Ltd Body weight gain inhibitors
AU2001298065A1 (en) * 2001-01-12 2003-09-02 Abbott Laboratories Process for the preparation of matrix metalloproteinase inhibitors
US20040077689A1 (en) * 2001-04-25 2004-04-22 Yasuo Sugiyama Abc expression promoters
AU2003256655A1 (en) * 2002-07-25 2004-02-16 Merck And Co., Inc. Therapeutic compounds for treating dyslipidemic conditions
PL378268A1 (pl) * 2002-11-26 2006-03-20 Pfizer Products Inc. Aktywatory PPAR
CN1319956C (zh) * 2003-09-12 2007-06-06 深圳市海粤门生物科技开发有限公司 一种噻唑烷二酮的衍生物及其药用制剂的制备方法和应用
DE602004022179D1 (de) * 2003-09-19 2009-09-03 Janssen Pharmaceutica Nv 4-((phenoxyalkyl)thio)-phenoxyessigsäuren und analoga
HUE028213T2 (en) 2003-09-19 2016-12-28 Janssen Pharmaceutica Nv 4 - ((Phenoxyalkyl) thio) -phenoxyacetic acid for use in the treatment of PPAR-delta-mediated conditions
EP1709014B1 (en) * 2004-01-20 2007-05-30 Merck & Co., Inc. Antidiabetic oxazolidinediones and thiazolidinediones
WO2006138328A1 (en) * 2005-06-14 2006-12-28 Merck & Co., Inc. Process for the production of antidiabetic oxazolidinediones
US7807692B2 (en) 2005-07-06 2010-10-05 Merck Sharp & Dohme Corp. Antidiabetic oxazolidinediones and thiazolidinediones
US20090069385A1 (en) * 2005-07-20 2009-03-12 Meinke Peter T Antidiabetic Oxazolidinediones and Thiazolidinediones
US7858666B2 (en) 2007-06-08 2010-12-28 Mannkind Corporation IRE-1α inhibitors
CN105001174A (zh) * 2015-07-14 2015-10-28 佛山市赛维斯医药科技有限公司 含苯并异恶唑和末端腈基苄基类结构的化合物及其用途
CN104987314A (zh) * 2015-07-14 2015-10-21 佛山市赛维斯医药科技有限公司 含苯并异恶唑和末端硝基苄基类结构的化合物及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3053490B2 (ja) * 1991-02-25 2000-06-19 杏林製薬株式会社 チアゾリジン−２，４−ジオン誘導体とその塩及び製造法
JP3906935B2 (ja) * 1995-12-18 2007-04-18 杏林製薬株式会社 Ｎ−置換ジオキソチアゾリジルベンズアミド誘導体及びその製造法
ES2202582T3 (es) * 1996-02-02 2004-04-01 MERCK & CO., INC. Agentes antidiabeticos.
WO1997028137A1 (en) * 1996-02-02 1997-08-07 Merck & Co., Inc. Heterocyclic derivatives as antidiabetic and antiobesity agents
DE69728267T2 (de) * 1996-02-02 2005-02-24 Merck & Co., Inc. Antidiabetisches mittel
US5801173A (en) * 1996-05-06 1998-09-01 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
CN1282325A (zh) 2001-01-31
PL340958A1 (en) 2001-03-12
NO20003112D0 (no) 2000-06-16
IS5506A (is) 2000-05-23
ID24878A (id) 2000-08-31
DE69836980D1 (de) 2007-03-15
ATE352545T1 (de) 2007-02-15
SK9212000A3 (en) 2001-02-12
JP3373198B2 (ja) 2003-02-04
CA2315397C (en) 2007-08-07
HUP0101366A2 (hu) 2001-09-28
CA2315397A1 (en) 1999-07-01
NO20003112L (no) 2000-08-18
EP1040102A1 (en) 2000-10-04
EP1040102B1 (en) 2007-01-24
AU740733B2 (en) 2001-11-15
EP1040102A4 (en) 2002-11-27
BG104602A (bg) 2001-01-31
JP2001526278A (ja) 2001-12-18
ES2281146T3 (es) 2007-09-16
KR20010033355A (ko) 2001-04-25
AU1833499A (en) 1999-07-12
WO1999032465A1 (en) 1999-07-01
IL136138A0 (en) 2001-05-20
BR9813801A (pt) 2000-10-03
TR200001753T2 (tr) 2000-11-21
DE69836980T2 (de) 2007-11-15

Similar Documents

Publication Publication Date Title
EA200000687A1 (ru) Производные арилтиазолидиндиона
ATE333448T1 (de) Arylthiazolidinedione und aryloxa zolidinedion- derivate
ATE362468T1 (de) N-substituierte indole mit anwendung in der behandlung von diabetes
DE60023492D1 (de) Glucagon antagonisten/inverse agonisten
EA200400149A1 (ru) Бензотиепины, обладающие активностью ингибиторов перемещения желчных кислот в подвздошной кишке и поглощения таурохолата
DE69435220D1 (de) Das Natrium Salz des (-)-Enantiomer von Omeprazole
NO20100656L (no) Modifiserte chimaere polypeptider med forbedrede farmakokinetiske egenskaper
WO2002026729A3 (en) Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders
FR2666218B1 (fr) Greffes vasculaires et leur procede de preparation.
EA200100703A1 (ru) Сочетания ингибиторов транспорта желчных кислот в подвздошной кишке и производных никотиновой кислоты для сердечно-сосудистых показаний
NO905291L (no) Fremgangsmaate for behandling av sinkholdige biprodukter og avfallsmaterialer.
DE69837148D1 (de) Chimäre proteine zur behandlung von diabetes
ES2173180T3 (es) Derivados del mercaptoacetilamida hipocolesterolemicos, antiateroescleroticos e hipotrigliceridemicos.
WO1996001430A3 (en) Screening for nuc inhibitors
DK0463063T3 (da) Hængselforbundet lamineret genstand
MY139550A (en) Indoles having anti-diabetic activity
DE69006964T2 (de) Behandlung von Hyperlipidemia mit 15-keto-Prostaglandin-Verbindungen.
ATE189392T1 (de) Hypocholesterolemische, antiatherosklerotische und hypotriglyceridemische verwendung von aminoacetylmercapto derivaten
KR900012622A (ko) 피부질환치료 조성물
AR018898A1 (es) Derivados de 5-aril-2,4-tiazolidindiona, una composicion farmaceutica que los comprende y el uso de los mismos para la fabricacion de un medicamento
DOP2003000770A (es) Indoles con actividad antibiabetica
FR2706128B1 (fr) Procédé de préparation de déjections animales, déjections animales désodorisées et leur utilisation .
ES1015531Y (es) Jeringuilla perfeccionada de unica utilizacion.
ES1006581Y (es) Torques-reloj perfeccionados de accion curativa.
FR2666584B1 (fr) Derives de riboses, leur preparation et leur application en therapeutique.